Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1628 1672
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18464519 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | Non-Final OA | Deciphera Pharmaceuticals, LLC |
| 18061091 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 17045916 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | Final Rejection | AURIGENE ONCOLOGY LIMITED |
| 19170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Non-Final OA | Amazentis SA |
| 18251759 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 17756422 | DIRECT AMPK ACTIVATOR COMPOUNDS COMBINED WITH INDIRECT AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18936782 | HALIDE-FREE AMMONIUM SILANES | Non-Final OA | TOPIKOS SCIENTIFIC, INC. |
| 18541691 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 18541733 | SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS | Non-Final OA | LUNELLA BIOTECH, INC. |
| 18259221 | SPIROCYCLIC COMPOUND AS KRAS-G12C INHIBITOR | Non-Final OA | Shanghai Youli Biopharma Co., Ltd. |
| 18562428 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS IN ANIMAL OF FAMILY CANIDAE, COMPRISING ENAVOGLIFLOZIN | Non-Final OA | DAEWOONG PHARMACEUTICAL CO., LTD. |
| 18543614 | ORAL FELINE FEED AND METHODS FOR CONTROLLING TICK INFESTATIONS IN A FELINE | Non-Final OA | In the Bowl Animal Health, Inc. |
| 18568791 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Non-Final OA | ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. |
| 18565626 | METHODS OF TREATMENT | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 18562560 | METHODS OF TREATING MITOCHONDRIA-RELATED DISORDERS | Non-Final OA | Rivus Pharmaceuticals, Inc. |
| 18562555 | RECEPTOR-INTERACTING PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Non-Final OA | CHENGDU BIOBEL BIOTECHNOLOGY CO., LTD |
| 17747938 | POLYMERIC EMULSION DELIVERY SYSTEMS | Final Rejection | BAUSCH HEALTH IRELAND LIMITED |
| 18011349 | ARIMOCLOMOL FOR TREATING GAUCHER DISEASE | Non-Final OA | ZEVRA DENMARK A/S |
| 18322174 | CONTROL OF RESISTANT PESTS | Non-Final OA | Bio-Gene Technology Limited |
| 18253588 | SOLID-STATE FORM OF HYDRATE OF CALCIUM OXYBATE, METHOD OF MAKING AND USE | Non-Final OA | Macfarian Smith Limited |
| 18031772 | USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS | Final Rejection | PACYLEX PHARMACEUTICALS INC. |
| 17588975 | Low-Dose Doxepin For Treatment Of Sleep Disorders In Elderly Patients | Non-Final OA | ProCom One, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy